相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Total body irradiation, etoposide, cyclophosphamide, and autologous peripheral blood stern-cell transplantation followed by randomization to therapy with interleukin-2 versus observation for patients with non-Hodgkin lymphoma: results of a phase 3 randomized trial by the Southwest Oncology Group (SWOG 9438)
John A. Thompson et al.
BLOOD (2008)
IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy
Christian S. Hinrichs et al.
BLOOD (2008)
Autocrine IL-6 signaling: A key event in tumorigenesis?
Sergei Grivennikov et al.
CANCER CELL (2008)
Interleukin-21 augments the efficacy of T-cell therapy by eliciting concurrent cellular and humoral responses
Takekazu Iuchi et al.
CANCER RESEARCH (2008)
Twelve immunotherapy drugs that could cure cancers
Martin A. ‘Mac’ Cheever
IMMUNOLOGICAL REVIEWS (2008)
Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines
Masahisa Jinushi et al.
IMMUNOLOGICAL REVIEWS (2008)
Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma
John A. Thompson et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Transient T cell depletion causes regression of melanoma metastases
Mary Ann Rasku et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2008)
Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: A meta-analysis of 18 trials involving 2,621 patients
Natalie J. Ives et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Interleukin-21 signaling: Functions in cancer and autoimmunity
Ian D. Davis et al.
CLINICAL CANCER RESEARCH (2007)
Interleukin-6 and its receptor in cancer - Implications for translational therapeutics
David S. Hong et al.
CANCER (2007)
Recognition of microorganisms and activation of the immune response
Ruslan Medzhitov
NATURE (2007)
Expression of interleukin-13 receptor α2 in glioblastoma multiforme:: Implications for targeted therapies
John S. Jarboe et al.
CANCER RESEARCH (2007)
Interleukin-12: Biological properties and clinical application
Michele Del Vecchio et al.
CLINICAL CANCER RESEARCH (2007)
Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains
Jinjuan Wang et al.
HUMAN GENE THERAPY (2007)
A full scale comparative study of methods for generation of functional Dendritic cells for use as cancer vaccines
Silvija Jarnjak-Jankovic et al.
BMC CANCER (2007)
An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma
Ian D. Davis et al.
CLINICAL CANCER RESEARCH (2007)
Phase I trial of BAY 50-4798, an interleukin-2-specific agonist in advanced melanoma and renal cancer
Kim Margolin et al.
CLINICAL CANCER RESEARCH (2007)
The IL-6/sIL-6R complex as a novel target for therapeutic approaches
Stefan Rose-John et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2007)
The IL-15/IL-15Rα on cell surfaces enables sustained IL-15 activity and contributes to the long survival of CD8 memory T cells
Noriko Sato et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma
Khuda D. Khan et al.
CLINICAL CANCER RESEARCH (2006)
A gene expression signature associated with survival in metastatic melanoma
Susanna Mandruzzato et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2006)
Combined IL-15/IL-15Rα immunotherapy maximizes IL-15 activity in vivo
Thomas A. Stoklasek et al.
JOURNAL OF IMMUNOLOGY (2006)
Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion
Daniel J. Powell et al.
JOURNAL OF IMMUNOLOGY (2006)
Cancer regression in patients after transfer of genetically engineered lymphocytes
Richard A. Morgan et al.
SCIENCE (2006)
IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo
Emmanuel Zorn et al.
BLOOD (2006)
The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design
Thomas A. Waldmann
NATURE REVIEWS IMMUNOLOGY (2006)
Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer
Michael J. Robertson et al.
CLINICAL CANCER RESEARCH (2006)
IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice
KL Knutson et al.
JOURNAL OF IMMUNOLOGY (2006)
Combined IL-21 and low-dose IL-2 therapy induces anti-tumor immunity and long-term curative effects in a murine melanoma tumor model
Hong He et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2006)
IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells
SA Rosenberg et al.
JOURNAL OF IMMUNOTHERAPY (2006)
IL-2 administration increases CD4+CD25hi Foxp3+ regulatory T cells in cancer patients
M Ahmadzadeh et al.
BLOOD (2006)
Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma
GC Cesana et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Signaling mechanisms, interaction partners, and target genes of STAT6
Daniel Hebenstreit et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2006)
New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions
CA Hunter
NATURE REVIEWS IMMUNOLOGY (2005)
Pharmacokinetics and in vitro and in vivo anti-tumor response of an interleukin-2-human serum albumin fusion protein in mice
RJ Melder et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2005)
The many faces of IL-7: From lymphopoiesis to peripheral T cell maintenance
TJ Fry et al.
JOURNAL OF IMMUNOLOGY (2005)
Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells
KS Kahlon et al.
CANCER RESEARCH (2004)
IL-21 enhances and sustains CD8+ T cell responses to achieve durable tumor immunity:: Comparative evaluation of IL-2, IL-15, and IL-21
A Moroz et al.
JOURNAL OF IMMUNOLOGY (2004)
STAT-1 is activated by IL-4 and IL-13 in multiple cell types
IM Wang et al.
MOLECULAR IMMUNOLOGY (2004)
Interleukin-21 is a T-helper cytokine that regulates humoral immunity and cell-mediated anti-tumour responses
PV Sivakumar et al.
IMMUNOLOGY (2004)
Generation of low-toxicity interleukin-2 fusion proteins devoid of vasopermeability activity
PS Hu et al.
BLOOD (2003)
IL-21 in synergy with IL-15 or IL-18 enhances IFN-γ production in human NK and T cells
M Strengell et al.
JOURNAL OF IMMUNOLOGY (2003)
Combined treatment with interleukin-18 and low-dose interleukin-2 induced regression of a murine sarcoma and memory response
YI Son et al.
JOURNAL OF IMMUNOTHERAPY (2003)
Interleukin-2 after autologous stem-cell transplantation for adult patients with acute myeloid leukemia in first complete remission
AS Stein et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells
MA Cooper et al.
BLOOD (2002)
Interleukin-12 in anti-tumor immunity and immunotherapy
MP Colombo et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2002)
Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis
A Kaser et al.
BLOOD (2001)
Cytokines and immune response in the tumor microenvironment
S Mocellin et al.
JOURNAL OF IMMUNOTHERAPY (2001)
A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivo
AB Shanafelt et al.
NATURE BIOTECHNOLOGY (2000)
分享论文
